| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and  APC/C complexes Cardozo T; Pagano MBMC Biochem  2007[Nov]; 8 Suppl 1 (Suppl 1): S9Recently, the ubiquitin proteasome system (UPS) has matured as a drug discovery  arena, largely on the strength of the proven clinical activity of the proteasome  inhibitor Velcade in multiple myeloma. Ubiquitin ligases tag cellular proteins,  such as oncogenes and tumor suppressors, with ubiquitin. Once tagged, these  proteins are degraded by the proteasome. The specificity of this degradation  system for particular substrates lies with the E3 component of the ubiquitin  ligase system (ubiquitin is transferred from an E1 enzyme to an E2 enzyme and  finally, thanks to an E3 enzyme, directly to a specific substrate). The clinical  effectiveness of Velcade (as it theoretically should inhibit the output of all  ubiquitin ligases active in the cell simultaneously) suggests that modulating  specific ubiquitin ligases could result in an even better therapeutic ratio. At  present, the only ubiquitin ligase leads that have been reported inhibit the  degradation of p53 by Mdm2, but these have not yet been developed into clinical  therapeutics. In this review, we discuss the biological rationale, assays,  genomics, proteomics and three-dimensional structures pertaining to key targets  within the UPS (SCFSkp2 and APC/C) in order to assess their drug development  potential. Publication history: Republished from Current BioData's Targeted  Proteins database (TPdb; http://www.targetedproteinsdb.com).|Anaphase-Promoting Complex-Cyclosome[MESH]|Animals[MESH]|Drug Delivery Systems/*methods[MESH]|Humans[MESH]|Protein Binding/genetics[MESH]|SKP Cullin F-Box Protein Ligases/genetics/*metabolism[MESH]|Ubiquitin-Protein Ligase Complexes/genetics/*metabolism[MESH]
 |